{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:18:35Z","timestamp":1788585515679,"version":"build-2803163510"},"reference-count":34,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Clinical Research Fund For Distinguished Young Scholars of Peking University Cancer Hospital","award":["QNJJ202204"],"award-info":[{"award-number":["QNJJ202204"]}]},{"award":["QNJJ202204"],"award-info":[{"award-number":["QNJJ202204"]}],"id":[{"id":"https:\/\/ror.org\/00nyxxr91","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Beijing Hospitals Authority Youth Programme","award":["QMIL20231114"],"award-info":[{"award-number":["QMIL20231114"]}]},{"award":["QMIL20231114"],"award-info":[{"award-number":["QMIL20231114"]}],"id":[{"id":"https:\/\/ror.org\/02jwb5s28","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Beijing hospitals Authority\u2019s Ascent Plan","award":["DFL20241101"],"award-info":[{"award-number":["DFL20241101"]}]},{"award":["DFL20241101"],"award-info":[{"award-number":["DFL20241101"]}],"id":[{"id":"https:\/\/ror.org\/02jwb5s28","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["L2608069"],"award-info":[{"award-number":["L2608069"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: This study evaluated neoadjuvant disitamab vedotin plus programmed cell death protein 1 (PD-1) blockade and associations of post-treatment neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) with response and progression-free survival (PFS) in muscle-invasive bladder cancer. Methods: This single-center retrospective cohort included 71 patients with cT2\u2013T3N0M0, human epidermal growth factor receptor 2 (HER2)-expressing disease treated between September 2021 and October 2025. Logistic regression and receiver operating characteristic analyses evaluated response endpoints; Kaplan\u2013Meier and Cox methods evaluated PFS. Benjamini\u2013Hochberg correction was applied separately to response analyses. Results: Complete response (CR), objective response, and disease control rates were 66.2%, 84.5%, and 88.7%. Of 47 CRs, 5 were cystectomy-confirmed pathological CR (pCR) and 42 were clinical CR (cCR). Response associations did not remain significant after correction (minimum q = 0.082). AUCs were 0.659\u20130.708. In a two-variable Cox model based on 14 PFS events, treatment cycles (HR 0.615, 95% CI 0.419\u20130.903; p = 0.013) and SII per 100 units (HR 1.205, 95% CI 1.073\u20131.355; p = 0.002) were associated with PFS, but these estimates require cautious interpretation. Two deaths occurred. Conclusions: Neoadjuvant disitamab vedotin plus PD-1 blockade showed promising antitumor activity. The pooled CR endpoint may overestimate pathological response and is not directly comparable with cystectomy-confirmed pCR. Without standardized pretreatment NLR and SII measurements, reverse causality cannot be excluded. Response associations and PFS findings based on 14 events require cautious interpretation and prospective validation.<\/jats:p>","DOI":"10.3390\/diagnostics16172802","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:05:26Z","timestamp":1788224726000},"page":"2802","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-Treatment NLR and SII Associations with Response and Progression-Free Survival After Neoadjuvant Disitamab Vedotin Plus PD-1 Blockade in Muscle-Invasive Bladder Cancer: A Real-World Cohort Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9030-243X","authenticated-orcid":false,"given":"Yongsheng","family":"Huang","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"given":"Yongpeng","family":"Ji","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"given":"Qiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5544-3339","authenticated-orcid":false,"given":"Yudong","family":"Cao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Jinchao","family":"Ma","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Ruijian","family":"You","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3095-5403","authenticated-orcid":false,"given":"Yongjie","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Peng","family":"Du","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dobruch, J., and Oszczud\u0142owski, M. (2021). Bladder cancer: Current challenges and future directions. Medicina, 57.","DOI":"10.3390\/medicina57080749"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2025 guidelines","volume":"87","author":"Bruins","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: A novel antibody-drug conjugate for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102085","DOI":"10.1016\/j.clgc.2024.102085","article-title":"Disitamab vedotin alone or in combination with immune checkpoint inhibitors in bladder-sparing treatment of muscle-invasive bladder cancer: A real-world study","volume":"22","author":"Wang","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1230395","DOI":"10.3389\/fphar.2023.1230395","article-title":"Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: A two-center real-world study","volume":"14","author":"Wei","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41698-025-01211-1","article-title":"Disitamab vedotin combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: A multicenter real-world study","volume":"10","author":"Guo","year":"2026","journal-title":"npj Precis Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e70033","DOI":"10.1002\/imt2.70033","article-title":"Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multicenter real-world study","volume":"4","author":"Hu","year":"2025","journal-title":"iMeta"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1549647","DOI":"10.3389\/fimmu.2025.1549647","article-title":"Disitamab vedotin versus gemcitabine-cisplatin regimen with immunotherapy: A comparative analysis of efficacy and safety in muscle-invasive bladder cancer","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1200\/JCO.2025.43.5_suppl.665","article-title":"Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial","volume":"43","author":"Sheng","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e70063","DOI":"10.1002\/imt2.70063","article-title":"Neoadjuvant immunotherapy driven bladder preservation for muscle invasive bladder cancer","volume":"4","author":"Hu","year":"2025","journal-title":"iMeta"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1200\/JCO.2024.42.23_suppl.113","article-title":"Efficacy and biomarker analysis of neoadjuvant disitamab vedotin combined with immunotherapy in patients with muscle-invasive bladder cancer: A multicenter real-world study","volume":"42","author":"Hu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1463173","DOI":"10.3389\/fonc.2024.1463173","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio for patients with bladder cancer undergoing radical cystectomy: A systematic review and meta-analysis","volume":"14","author":"Chen","year":"2024","journal-title":"Front. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kaczmarek, K., Ma\u0142kiewicz, B., Gurwin, A., Krawczyk, W.M., Skonieczna-\u017bydecka, K., and Lemi\u0144ski, A. (2024). Prognostic value of postneoadjuvant chemotherapy neutrophil-to-lymphocyte ratio in patients undergoing radical cystectomy. J. Clin. Med., 13.","DOI":"10.3390\/jcm13071953"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clgc.2023.01.008","article-title":"Predictive and prognostic role of the neutrophil-to-lymphocyte ratio in muscle invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy","volume":"21","author":"Schuettfort","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1707657","DOI":"10.3389\/fonc.2025.1707657","article-title":"Prognostic value of the systemic immune-inflammation index in bladder cancer: An updated evidence-based analysis","volume":"15","author":"Bai","year":"2025","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1486389","DOI":"10.3389\/fonc.2024.1486389","article-title":"Prognostic role of prognostic nutritional index in patients with bladder cancer: A systematic review and meta-analysis","volume":"14","author":"Sun","year":"2024","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): A phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11255-014-0866-z","article-title":"Prognostic role of HER2 expression in bladder cancer: A systematic review and meta-analysis","volume":"47","author":"Zhao","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wang, D., Cao, M., Zhang, Y., Bi, L., Chen, M., Ni, M., Zheng, Q., Yao, K., Liu, Z., and Yang, X. (2025). RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: A multicenter, real-world, retrospective study. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14154-4"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","article-title":"Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer: Analysis of GETUG\/AFU V05 VESPER secondary endpoints","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2281654","DOI":"10.1080\/07853890.2023.2281654","article-title":"Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and meta-analysis","volume":"55","author":"Wang","year":"2023","journal-title":"Ann. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10238-024-01408-x","article-title":"Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: A systematic review and meta-analysis","volume":"24","author":"Yu","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","article-title":"Therapeutic potential of tumor-associated neutrophils: Dual role and phenotypic plasticity","volume":"10","author":"Zhou","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1342996","DOI":"10.3389\/fonc.2024.1342996","article-title":"Prognostic and clinicopathological significance of systemic immune-inflammation index in upper tract urothelial carcinoma: A meta-analysis of 3911 patients","volume":"14","author":"Yu","year":"2024","journal-title":"Front. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e34361","DOI":"10.1016\/j.heliyon.2024.e34361","article-title":"The impact of platelets on the metastatic potential of tumour cells","volume":"10","author":"Raskov","year":"2024","journal-title":"Heliyon"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s44276-024-00058-6","article-title":"Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors","volume":"2","author":"Conroy","year":"2024","journal-title":"BJC Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17588359241305091","DOI":"10.1177\/17588359241305091","article-title":"Combining serum inflammatory markers and clinical factors to predict survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors","volume":"16","author":"Cheng","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lee, H.W., Kwon, W.A., Nguyen, N.T., Phan, D.T.T., and Seo, H.K. (2023). Approaches to clinical complete response after neoadjuvant chemotherapy in muscle-invasive bladder cancer: Possibilities and limitations. Cancers, 15.","DOI":"10.3390\/cancers15041323"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wu, J., Xie, R.Y., Cao, C.Z., Shang, B.Q., Shi, H.Z., and Shou, J.Z. (2022). Disease management of clinical complete responders to neoadjuvant chemotherapy of muscle-invasive bladder cancer: A review of literature. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.816444"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/17\/2802\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:57:13Z","timestamp":1788584233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/17\/2802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":34,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["diagnostics16172802"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16172802","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}